Alder Biopharmaceuticals, Inc.
6 clinical trials · Sponsor
◉ Watch Alder Biopharmaceuticals, Inc.
| Record | Firm | Date |
|---|---|---|
| An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine (NCT02985398) | Alder Biopharmaceuticals, Inc. | 2016-12-01 |
| Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine (NCT02974153) | Alder Biopharmaceuticals, Inc. | 2016-11-01 |
| A Multicenter Assessment of ALD403 in Frequent Episodic Migraine (NCT02559895) | Alder Biopharmaceuticals, Inc. | 2015-09-01 |
| A Multicenter Assessment of ALD403 in Chronic Migraine (NCT02275117) | Alder Biopharmaceuticals, Inc. | 2014-10-01 |
| Safety, Efficacy and Pharmacokinetics of ALD403 (NCT01772524) | Alder Biopharmaceuticals, Inc. | 2013-01-01 |
| Safety Tolerability and Pharmacokinetics of ALD403 (NCT01579383) | Alder Biopharmaceuticals, Inc. | 2012-04-01 |
Track Alder Biopharmaceuticals, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.